Amgen makes biologic medicines for chronic diseases like arthritis, osteoporosis, and cancer, selling them to hospitals and pharmacies worldwide.
Money comes from selling drugs like Enbrel, Prolia, and Repatha, with gross margins around 72% and net margins near 23%, driven by recurring prescriptions.
Biologic manufacturing complexity and patent protection deter generic competition from companies like Pfizer and Novartis, but biosimilar erosion from Samsung Bioepis and others is weakening pricing power.
Buy (sector percentile 69) — value B, growth B+, profitability A, momentum B, revisions B-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Cane Capital raised stake 73.2%; shares hit new highs alongside MRK, signaling investor interest
Multiple sources confirm Q2 beat and raised 2026 outlook despite biosimilar pressure
Law firm investigates patient data exposure, ongoing legal action
Multiple sources mention Amgen's earnings timing, market watches results
EMA's CHMP issued positive opinion supporting expanded indication for Repatha
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
